Evanthia Bernitsas Selected Research

Evanthia Bernitsas Research Topics

16	Multiple Sclerosis 01/2024 - 01/2006
4	Atrophy 01/2024 - 01/2017
4	Ganglion Cysts (Ganglion) 01/2024 - 05/2016
4	Disease Progression 01/2024 - 06/2020
2	Relapsing-Remitting Multiple Sclerosis 01/2024 - 01/2021
2	Cognitive Dysfunction 01/2024 - 02/2021
2	Fatigue 12/2023 - 05/2019
2	Inflammation (Inflammations) 02/2023 - 01/2023
2	COVID-19 01/2021 - 11/2020
2	Infections 11/2020 - 01/2018
1	Post-Acute COVID-19 Syndrome 01/2023
1	Anosmia 01/2023
1	Neuroinflammatory Diseases 01/2023
1	Olfaction Disorders (Cacosmia) 01/2023
1	Neurocutaneous Syndromes (Phakomatoses) 01/2022
1	Hamartoma 01/2022
1	Tuberous Sclerosis (Bourneville's Disease) 01/2022
1	Progressive Multifocal Leukoencephalopathy 11/2021
1	Hearing Loss (Hearing Impairment) 02/2021
1	Obesity 01/2021
1	Myasthenia Gravis 01/2020
1	Dysphonia (Spastic Dysphonia) 07/2019
1	Neoplasms (Cancer) 01/2018
1	Cardiotoxicity 01/2006

5	Retinaldehyde (Retinal)IBA 01/2024 - 05/2016
5	Biomarkers (Surrogate Marker)IBA 01/2024 - 06/2019
2	Protons (Proton)IBA 12/2023 - 05/2019
1	Oxygen (Dioxygen)IBA 01/2024
1	ocrelizumabIBA 08/2023
1	trans-sodium crocetinate (crocetin)IBA 01/2022
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2021
1	mesoglycanIBA 01/2021
1	ferumoxtran-10 (ultrasmall superparamagnetic iron oxide)IBA 01/2021
1	CytokinesIBA 11/2020
1	InflammasomesIBA 11/2020
1	Indicators and Reagents (Reagents)IBA 10/2020
1	glucose-mannose-glucoseIBA 01/2020
1	zilucoplanIBA 01/2020
1	Complement Inactivating AgentsIBA 01/2020
1	AutoantibodiesIBA 01/2020
1	Cholinergic ReceptorsIBA 01/2020
1	Botulinum Toxins (Botulinum Toxin)IBA 07/2019
1	Rituximab (Mabthera)FDA Link 01/2018
1	Oligoclonal BandsIBA 01/2017
1	Immunoglobulin G (IgG)IBA 01/2017
1	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2006
1	Dexrazoxane (Zinecard)FDA LinkGeneric 01/2006